FDA approves Obecure's obesity drug

Obesity-drug startup Obecure, which is part of the Biolight group has received FDA approval for starting Phase 2 clinical trials of OBE 101, its drug for weight control on human beings.

By SHARON WROBEL
September 5, 2006 09:19

Obesity-drug startup Obecure, which is part of the Biolight group has received FDA approval for starting Phase 2 clinical trials of OBE 101, its drug for weight control on human beings. Obecure is already in contact with 20 medical centers in the U.S. to run the trials and to begin giving patients its drug. The first trials are expected to start the coming January to avoid the Christmas holidays, a period in which people tend to put on weight.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 12 - 22
    Beer Sheva
    12 - 21
    Tel Aviv - Yafo
  • 11 - 16
    Jerusalem
    13 - 19
    Haifa
  • 16 - 25
    Elat
    13 - 20
    Tiberias